DFTX
Definium Therapeutics, Inc.
NASDAQ · Healthcare · Medical - Pharmaceuticals · US
$38.09
+0.24%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- -74.6%
- EPS
- —
- Free cash flow
- -64.3%
- Operating cash flow
- -64.3%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +47.0%
- EPS
- +36.6%
Three-year CAGR
- Revenue
- —
- EBITDA
- -68.4%
- EBIT
- -60.0%
- Net income
- -69.1%
- EPS
- -33.8%
- Free cash flow
- -66.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026